Management

Peter Altman, PhD
President & CEO, Director

Dr. Peter Altman was founding CEO for XDX, Inc., a developer of gene based assays for monitoring cardiac transplant rejection, which was separated from BioCardia in 2002. Peter remains a member of the board of directors of XDx and is also a managing director of Lumen Therapeutics, an early stage pharmaceutical company for treating cardiac bypass grafts during surgery. Previously, Peter was with St. Jude Medical developing implantable cardiac defibrillation systems. Peter received his Doctorate in bioengineering/ pharmaceutical chemistry from the University of California San Francisco and University of California Berkeley, his Management of Technology certificate from the Haas School of Business, University of California Berkeley, and both his Master of Science and Bachelors of Science degrees in Mechanical Engineering from the Columbia University School of Engineering and Applied Sciences. Peter has more than 20 years of experience in life science product development and management.

Andrew Mackenzie
Vice President of Operations

Mr. Andrew Mackenzie was most recently Vice President of Research & Development at StemCor Systems, where he was responsible for the initial product development efforts. Previously, Andy was head of Quality, Clinical and Regulatory Affairs at Sadra Medical, a start-up company focused on percutaneous delivery of a replacement aortic heart valve, General Manager at Perfect Surgical, a Palo Alto based start-up company developing a novel electro-surgical device, Director of Research and Development at InnerDyne Medical, a maker of minimally invasive surgery products, and Technical Project Leader at Guidant Corporation, a maker of products for the treatment of cardiovascular disease. Andy received his Master of Business Administration from Santa Clara University, his Master of Science in Mechanical Engineering from the University of California at Berkeley, his Bachelor of Science in Mechanical Engineering from Cal Poly, San Luis Obispo, and has over 20 years of engineering and management experience in large and small companies.

David Snow
Vice President of Research and Development, Devices

Mr. David Snow was Director of Research and Development and New Business Development at XTENT, managing delivery system development efforts from inception to its IPO in 2007. Prior to joining Xtent, he guided early development efforts on a ventricular assist device for Sunshine Heart Company. Prior, David served as Vice President of R&D for FoxHollow Technologies where he was responsible for the development of an atherectomy catheter and for building the engineering team. He also held engineering management roles at Heartport and Devices for Vascular Intervention. David holds a BS in Mechanical Engineering from Tufts University and a MS in Mechanical Engineering from Stanford University. He is an inventor on 17 issued U.S. patents and has over 20 years of engineering and management experience.

Gulshan Shaver
Vice President of Intellectual Property and Licensing

Ms. Gulshan Shaver was most recently General Counsel for Singulex, Inc., a diagnostics company, where she established a strong intellectual property presence in the field of high sensitivity biomarker tests for cardiovascular disease management. Previously, Ms Shaver was Vice President, Legal Affairs at Perlegen Sciences, Inc., a pharmacogenomics company, Intellectual Property Counsel at Caliper Technologies, Inc. Ms. Shaver has a technical background with academic training in organic chemistry and chemical engineering. Prior to starting her legal career, she was a research scientist at several leading pharmaceutical companies, including Allergan, Syntex and Gilead Sciences.

Didier Rouy, MD PhD
Vice President of Scientific and Clinical Affairs

Dr. Didier Rouy was most recently director of the Laboratory of Cardiovascular Research in Luxembourg, a laboratory focusing on molecular mechanisms of heart failure. There, he created a cardiovascular stem cell therapy program. Previously, Didier was Manager of Cardiovascular Research at Gencell SAS, the gene-therapy focused affiliate of Aventis Pharmaceuticals, where he moved a pro-angiogenic gene therapy product from the basic concept to a US phase II clinical trial. Didier holds a Doctorate of Medicine and a Doctorate of Sciences in Protein Biochemistry from Paris, France, as well as the prestigious Doctorate of State in Biology. He completed a post-doctorate in molecular biology in the Lawrence Berkeley Laboratory in Berkeley. Didier has 20 years of experience in the pharmaceutical industry and public research.

Robert Chin, PhD
Acting Vice President, Regulatory Affairs

Dr. Robert Chin was formerly the Vice President, Regulatory and Clinical Affairs and Quality Assurance at Baxter Healthcare, Pacesetter, Heartport, and Align Technologies. Bob holds a Doctorate in chemical engineering from UCLA and has thirty years experience in the medical device industry.